GTHX - Stock Analysis & Overview

About G1 Therapeutics, Inc.

Biotechnology

Healthcare

G1 Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer. The company offers COSELA, which helps to decrease chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer...

G1 Therapeutics, Inc. Key Metrics

Market Cap: $377M
52 Weeks Low: $1.08
52 Weeks High: $7.19
P/B: 15.26x
P/E: -8.38x
P/S: 6.48x

Upcoming Events

GTHX Analyst Forecasts

‌

GTHX Financials

GTHX Income Statement Key Metrics

Revenue(TTM)58.20 M
Gross Profit(TTM)52.05 M
EBITDA(TTM)-37.52 M
Net Income(TTM)-44.77 M
EPS Diluted(TTM)-0.86

Decode GTHX's Latest Earnings Call with Ease

Tap 'Generate' for a crystal-clear,
AI-crafted summary and stay ahead in the investment game!

GTHX earnings and revenue history

Gross Profit Margin vs Peers

Profit margin ratio of GTHX (0.913) is higher than the average of its peers (-121.242).

Net Profit Margin vs Peers

Net profit margin ratio of GTHX (-0.581) is higher than the average of its peers (-165.053).

GTHX Return on Equity

See how efficiently GTHX generates profit for it's shareholders.

-135.55%

100

Poor

Average

Strong

Return on Equity vs Peers

Return on Equity ratio of GTHX (-1.356) is lower than the average of its peers (-0.626).

Return on Equity Growth

GTHX's Return on Equity has shown poor growth over the past 10 years, increasing by only -4.13%.

GTHX Revenue Growth

See how GTHX has grown it's revenue over the past 10 years.

‌

Revenue Growth

GTHX's revenue has grown significantly over the past 10 years, increasing by over 54.82%.

G1 Therapeutics, Inc.

Page title

Section title